Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.

Krämer J, Lenders M, Canaan-Kühl S, Nordbeck P, Üçeyler N, Blaschke D, Duning T, Reiermann S, Stypmann J, Brand SM, Gottschling T, Störk S, Wanner C, Sommer C, Brand E, Weidemann F.

Nephrol Dial Transplant. 2018 Aug 1;33(8):1362-1372. doi: 10.1093/ndt/gfx319.

PMID:
29186537
2.

A Comparison of Different Algorithms for the Assessment of Cardiovascular Risk in Patients at Waiting List for Kidney Transplantation.

Reuter S, Reiermann S, Malyar V, Schütte-Nütgen K, Schmidt R, Pavenstädt H, Reinecke H, Suwelack B.

PLoS One. 2016 Oct 21;11(10):e0161927. doi: 10.1371/journal.pone.0161927. eCollection 2016.

3.

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.

Lenders M, Weidemann F, Kurschat C, Canaan-Kühl S, Duning T, Stypmann J, Schmitz B, Reiermann S, Krämer J, Blaschke D, Wanner C, Brand SM, Brand E.

Orphanet J Rare Dis. 2016 May 4;11(1):54. doi: 10.1186/s13023-016-0441-z.

4.

Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.

Lenders M, Canaan-Kühl S, Krämer J, Duning T, Reiermann S, Sommer C, Stypmann J, Blaschke D, Üçeyler N, Hense HW, Brand SM, Wanner C, Weidemann F, Brand E.

J Am Soc Nephrol. 2016 Mar;27(3):952-62. doi: 10.1681/ASN.2015030337. Epub 2015 Jul 16.

5.

Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.

Weidemann F, Krämer J, Duning T, Lenders M, Canaan-Kühl S, Krebs A, Guerrero González H, Sommer C, Üçeyler N, Niemann M, Störk S, Schelleckes M, Reiermann S, Stypmann J, Brand SM, Wanner C, Brand E.

J Am Soc Nephrol. 2014 Apr;25(4):837-49. doi: 10.1681/ASN.2013060585. Epub 2014 Feb 20.

6.

Influence of erythropoietin on arterial stiffness and endothelial function in renal transplant recipients.

Bartels V, Hillebrand U, Kosch M, Hausberg M, Kisters K, Di Marco GS, Reiermann S, Pavenstaedt H, Lang D.

Am J Nephrol. 2012;36(4):355-61. doi: 10.1159/000343140. Epub 2012 Oct 4.

PMID:
23038220
7.

High phosphate directly affects endothelial function by downregulating annexin II.

Di Marco GS, König M, Stock C, Wiesinger A, Hillebrand U, Reiermann S, Reuter S, Amler S, Köhler G, Buck F, Fobker M, Kümpers P, Oberleithner H, Hausberg M, Lang D, Pavenstädt H, Brand M.

Kidney Int. 2013 Feb;83(2):213-22. doi: 10.1038/ki.2012.300. Epub 2012 Aug 22.

8.

Age-related penetrance of hereditary atypical hemolytic uremic syndrome.

Sullivan M, Rybicki LA, Winter A, Hoffmann MM, Reiermann S, Linke H, Arbeiter K, Patzer L, Budde K, Hoppe B, Zeier M, Lhotta K, Bock A, Wiech T, Gaspert A, Fehr T, Woznowski M, Berisha G, Malinoc A, Goek ON, Eng C, Neumann HP.

Ann Hum Genet. 2011 Nov;75(6):639-47. doi: 10.1111/j.1469-1809.2011.00671.x. Epub 2011 Sep 12.

9.

Effect of different synthetic membranes on laboratory parameters and survival in chronic haemodialysis patients.

Kreusser W, Reiermann S, Vogelbusch G, Bartual J, Schulze-Lohoff E.

NDT Plus. 2010 May;3(Suppl 1):i12-i19.

10.

IF/TA-related metabolic changes--proteome analysis of rat renal allografts.

Reuter S, Reiermann S, Wörner R, Schröter R, Edemir B, Buck F, Henning S, Peter-Katalinic J, Vollenbröker B, Amann K, Pavenstädt H, Schlatter E, Gabriëls G.

Nephrol Dial Transplant. 2010 Aug;25(8):2492-501. doi: 10.1093/ndt/gfq043. Epub 2010 Feb 22.

PMID:
20176611
11.

Quality of life, coping, and mental health status after living kidney donation.

Wiedebusch S, Reiermann S, Steinke C, Muthny FA, Pavenstaedt HJ, Schoene-Seifert B, Senninger N, Suwelack B, Buyx AM.

Transplant Proc. 2009 Jun;41(5):1483-8. doi: 10.1016/j.transproceed.2009.02.102.

PMID:
19545662
12.

[A new tool for job evaluation].

Reiermann S.

Sygeplejersken. 1972 Jul 6;72(26):10-3. Danish. No abstract available.

PMID:
4489326

Supplemental Content

Loading ...
Support Center